Literature DB >> 17869065

Orienting of attention in unmedicated patients with schizophrenia, prodromal subjects and healthy relatives.

Euphrosyne Gouzoulis-Mayfrank1, Maryam Balke, Soulmaz Hajsamou, Stephan Ruhrmann, Frauke Schultze-Lutter, Joerg Daumann, Karsten Heekeren.   

Abstract

In typical orienting of attention tasks subjects have to respond as fast as possible to targets which appear in the periphery of the visual field and are preceded by spatial cues (e.g. brightening of a peripheral box where the target may subsequently appear). Reaction times (RT) are facilitated when cue and target appear at the same location (valid cueing) and the cue target interval is short (<250 ms). However, RTs slow down again when the target follows a valid cue after an interval of 250 ms and longer. This latter phenomenon is called Inhibition of Return (IOR) and is thought to reflect an automatic, inhibitory mechanism to protect the organism from redundant and distracting stimuli. Deficits of IOR were repeatedly reported in patients with schizophrenia. However, the role of medications and the nature of the deficit (trait or vulnerability indicator?) were unclear. In the present study we examined 15 unmedicated patients with schizophrenia (age: 31.2+/-11.1, m/f: 11/4, global scores SAPS: 48.33+/-33.09, SANS: 19.22+/-26.16), 29 subjects who were putatively in a prodromal state of psychosis, 30 first-degree relatives, another 8 first-degree relatives who had one child and at least one more relative with schizophrenia, and 50 healthy controls. We found an impairment of IOR only in the unmedicated patient group. In conclusion, blunted IOR in schizophrenia is not secondary to medications. According to this and previous studies blunted IOR may be most probably viewed as a trait cognitive feature of the schizophrenic disorder.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17869065     DOI: 10.1016/j.schres.2007.06.028

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  14 in total

1.  Psilocybin-induced deficits in automatic and controlled inhibition are attenuated by ketanserin in healthy human volunteers.

Authors:  Boris B Quednow; Michael Kometer; Mark A Geyer; Franz X Vollenweider
Journal:  Neuropsychopharmacology       Date:  2011-09-28       Impact factor: 7.853

2.  Enhanced facilitation of spatial attention in schizophrenia.

Authors:  Kevin M Spencer; Paul G Nestor; Olga Valdman; Margaret A Niznikiewicz; Martha E Shenton; Robert W McCarley
Journal:  Neuropsychology       Date:  2011-01       Impact factor: 3.295

3.  Visuospatial attention in schizophrenia: deficits in broad monitoring.

Authors:  Britta Hahn; Benjamin M Robinson; Alexander N Harvey; Samuel T Kaiser; Carly J Leonard; Steven J Luck; James M Gold
Journal:  J Abnorm Psychol       Date:  2011-05-23

Review 4.  CNTRICS final task selection: control of attention.

Authors:  Keith H Nuechterlein; Steven J Luck; Cindy Lustig; Martin Sarter
Journal:  Schizophr Bull       Date:  2009-01       Impact factor: 9.306

5.  The effects of a DTNBP1 gene variant on attention networks: an fMRI study.

Authors:  Markus Thimm; Axel Krug; Thilo Kellermann; Valentin Markov; Sören Krach; Andreas Jansen; Klaus Zerres; Thomas Eggermann; Tony Stöcker; N Jon Shah; Markus M Nöthen; Marcella Rietschel; Tilo Kircher
Journal:  Behav Brain Funct       Date:  2010-09-16       Impact factor: 3.759

Review 6.  Turning it upside down: areas of preserved cognitive function in schizophrenia.

Authors:  James M Gold; Britta Hahn; Gregory P Strauss; James A Waltz
Journal:  Neuropsychol Rev       Date:  2009-05-19       Impact factor: 7.444

7.  An auditory processing abnormality specific to liability for schizophrenia.

Authors:  Rachel B Force; Noah C Venables; Scott R Sponheim
Journal:  Schizophr Res       Date:  2008-06-20       Impact factor: 4.939

8.  Pharmacological modulation of the neural basis underlying inhibition of return (IOR) in the human 5-HT2A agonist and NMDA antagonist model of psychosis.

Authors:  Jörg Daumann; Karsten Heekeren; Anna Neukirch; Christiane M Thiel; Walter Möller-Hartmann; Euphrosyne Gouzoulis-Mayfrank
Journal:  Psychopharmacology (Berl)       Date:  2008-07-24       Impact factor: 4.530

9.  Auditory orienting and inhibition of return in schizophrenia: a functional magnetic resonance imaging study.

Authors:  Christopher C Abbott; Flannery Merideth; David Ruhl; Zhen Yang; Vincent P Clark; Vince D Calhoun; Faith M Hanlon; Andrew R Mayer
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2011-12-30       Impact factor: 5.067

10.  "To see or not to see: that is the question." The "Protection-Against-Schizophrenia" (PaSZ) model: evidence from congenital blindness and visuo-cognitive aberrations.

Authors:  Steffen Landgraf; Michael Osterheider
Journal:  Front Psychol       Date:  2013-07-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.